

Developing a breakthrough allogeneic cell therapy

February 2023

Two major innovations of the Scarcell hGF technology

1 **Human Gingival Fibroblasts (hGF) with exceptional healing properties**

- **5 animal models**
- **10 peer-reviewed international publications**
- Classified on April 13, 2022, as **"Tissue engineered product" by the EMA** in the Advanced Therapy Medicinal Product (ATMP) classification

2 **hGF cultured with an efficient and scalable GMP bio-production process**

1 surgery gum scrap (0.5g)

1.3 million vials

- Unique approach
- Safe and effective cell therapy at a reasonable cost

Why Gingival Fibroblasts?

The healing process
leaves an indelible mark on the
injured organ.

This exceptional tissue repair and restorative property is carried out by the gingival fibroblasts.

The gum is the organ most attacked daily, undergoing thermal, physical, chemical and bacteriological aggressions.

Despite these aggressions, the gum remains intact and functional without any scarring.

Unique Properties of Allogeneic Gingival Fibroblasts for Tissue Repair

- Based on solid scientific work in different animal models:

- Aneurysm Experimental arthrosis

- Degenerative arthrosis

- Post traumatic arthrosis

- Radic burn
- Pressure ulcer
- Aneurysm

Powerful anti-inflammatory action

Immuno-modulation, inhibition of pro-inflammatory cytokines, IL1, IL6, overexpression of anti-inflammatory cytokines, IL4, TGFB

Tissue restored with the original phenotype

Restoring skin, cartilage, and vessel

Long-lasting therapeutic action

Thanks to immuno-evasion (expression of the CD47 and MHC-1 markers)

Treatment without efficacy loss for up to several months

Safe allogeneic therapy
No apparent toxicity

Not requiring the addition of immunosuppressive agents

IP portfolio

Application driven patent portfolio

First targeted indications	Geographies
Osteoarthritis	
Wound healing *Pressure Ulcer*	

- Positive FTO analysis completed

Umbrella patent application protecting uses of hGFs

Product

- **Filing of a new composition of matter patent** covering the novel sub-population, for any therapeutic use
- Genetic, phenotypic and functionality description of hGF after bioproduction
- Secure the use of hGF as "raw material"

Production

- Production process
- Patent on the method

GF cell therapy, a technology with multiple clinical indications

Pipeline



Other potential indications demonstrated by experimental research



Sources: Scarcell confidential data
** Potential additional indications/opportunities to be confirmed*

A qualified team to carry Scarcell Therapeutics development

Pr. ANTOINE LAFONT
Founder

Head, interventional cardiology, European Hospital Georges Pompidou, Paris

Co-founder, ARTERIAL REMODELLING TECHNOLOGIES, sold to Terumo in 2014

SARAH SORREL
Chief Executive Officer (CEO)

Founder of MedPass, leading CRO in the EU for medtech acquired by ICON in 2020

Board Member at two cardiovascular device start ups

JONATHAN SUSINI
Chief Financial Officer (CFO)

12 years of experience

Ricol Lasteyrie Corporate Finance, M&A

EY Transaction Advisory Services

MATHIEU CASTÉLA
Chief Scientific Officer (CSO)

PhD in cell therapy

10 years of experience in cell therapy

Former Project Leader at Imagine Institute, Paris

ALEXANDRINE MAHOUDEAU
Preclinical manager

PhD

Institut de Myologie, La Pitié Salpêtrière

EMELINE BELLE
Study Engineer

Master 2 Biology, Physiology, Molecular and Cellular Pathology

Laboratory technician, Laboratoires Servier